NEW YORK (GenomeWeb) – Natera reported after the close of the market Thursday that its third quarter 2015 revenues were down 3 percent from its third quarter 2014 revenues.

The San Carlos, California-based molecular diagnostics company brought in total revenue of $44.9 million in the quarter, down from $46.3 million in Q3 2014, but beating Wall Street's average estimate of $43.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.